Triple attack on lung scarring: could plasma exchange and immune therapy slow IPF?
NCT ID NCT07674745
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This Phase II trial tests whether a combination of therapeutic plasma exchange (filtering the blood), rituximab (a drug that targets certain immune cells), and intravenous immunoglobulin (IVIg) can slow lung decline in people with progressive idiopathic pulmonary fibrosis (IPF). The study enrolls 52 adults aged 40–85 with worsening IPF. Participants receive either this triple therapy plus usual care, or usual care alone, and researchers track changes in lung function, oxygen needs, and walking distance over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
therapeutic plasma exchange, rituximab, and intravenous immunoglobulin
What this could lead to
If successful, this combination could offer a new way to slow lung function decline in people with progressive IPF, potentially delaying the need for oxygen or transplant.
What could go wrong
This is a mid-stage trial with only 52 participants, so results may not apply to all IPF patients. The treatment involves multiple procedures and carries risks like infection or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Loyola University
Chicago, Illinois, 60153, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwestern University
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Temple University
Philadelphia, Pennsylvania, 19140, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Alabama at Birmingham
Birmingham, Alabama, 35216, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas
Kansas City, Kansas, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Utah
Salt Lake City, Utah, 84132, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact